TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01345175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
Study: NCT01992224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mechanical Ventilation
Description: Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Mechanical Ventilation
Description: other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
Study: NCT03584815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery/Fasciotomy
Description: Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
Study: NCT00608049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate and low glycemic index (GI) diet
Description: The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate and low glycemic index (GI) diet
Description: The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
Study: NCT02320630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
Study: NCT03838003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERIC protocol
Description: ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
Study: NCT01576406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg once a day
Study: NCT01576406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg once a day
Study: NCT00608049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate and high GI diet
Description: The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
Study: NCT03573245

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Tranexamic acid effect on perioperative bleeding in orthopedic surgery

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Tranexamic acid effect on perioperative bleeding in orthopedic surgery

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Tranexamic acid effect on perioperative bleeding in orthopedic surgery
Study: NCT02393339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Pre-operative administration of Paracetamol syrup

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pre-operative administration of placebo syrup
Study: NCT02186756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback and Usual care
Description: Please refer to arm description
Study: NCT00771212

Intervention type: OTHER
Intervention: Observational pain control study
Description: Observational pain control study
Study: NCT01907607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day.
Study: NCT03282526

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Whole body plethysmography
Description: Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
Study: NCT00589277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed counseling & Gain-framed materials
Description: Novel messages for quitting smoking

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care counseling + standard materials
Description: Standard messages for quitting smoking
Study: NCT02292498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR ONE
Study: NCT01267604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH (rFSH)
Description: 225IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rFSH + Inositol + Melatonin
Description: 225IU rFSH, 4g Inositol, 3mg Melatonin
Study: NCT00364819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
Study: NCT04939870

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical parameters evaluation
Description: selected biochemical parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical parameters evaluation
Description: selected biochemical parameters
Study: NCT02288182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann VivOss
Description: Patients will receive Straumann VivOss for sinus augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss
Description: Patients will receive Geistlich Bio-Oss for sinus augmentation.
Study: NCT04939870

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical parameters evaluation
Description: selected biochemical parameters
Study: NCT02381951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation (St Jude Medical)
Description: implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
Study: NCT01055132

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lens
Description: contact lens to correct astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lens
Description: contact lens to correct astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lens
Description: contact lens to correct astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lens
Description: contact lens to correct astigmatism
Study: NCT06032962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingectomy
Description: surgical removal of the fallopian tubes
Study: NCT01159197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
Study: NCT01342536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)
Description: The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)
Description: The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)
Study: NCT01395641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gene therapy
Description: AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
Study: NCT02218970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Study: NCT03549117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Right Tan (small/medium) nasal strips
Description: Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal strip
Description: Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
Study: NCT03148756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
Study: NCT00696436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
Study: NCT02218970

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no training (control)
Study: NCT01070459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Description: The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
Study: NCT00696436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, orally, once daily for up to six weeks.
Study: NCT01070459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up first aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up first aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
Study: NCT03273504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
Description: The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
Study: NCT01070459

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up control group
Description: No intervention will be offered in a period of 9 months after the passive mobilisation programme

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up control group
Description: No intervention will be offered in a period of 9 months after the passive mobilisation programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up second aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up second aerobic exercise group
Description: The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
Study: NCT00345839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Study: NCT02172768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternate dosing
Description: treatment for 8 days with intravenous micafungin twice weekly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: daily dosing
Description: micafungin daily for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micafungin
Study: NCT03506100

Intervention type: OTHER
Group type: OTHER
Intervention: Water Walking
Description: Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
Study: NCT00221403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone oral solution
Description: liquid, BID dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Oral Solution
Description: liquid, BID dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid, BID dosing.
Study: NCT01430793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 600,000 units IM
Description: Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml